Paul Tudor Jones's CRSP Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 39,468 shares of CRISPR Therapeutics AG (CRSP) worth $2.07 M, representing 0.00% of the portfolio. First purchased in 2018-Q1, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 46,999 shares. Largest reduction occurred in Q2 2025, reducing 51,242 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +39,468 | New Buy | 39,468 | $52.44 |
| Q2 2025 | -51,242 | Sold Out | 0 | $0.00 |
| Q1 2025 | +32,905 | Add 179.45% | 51,242 | $34.03 |
| Q4 2024 | -28,662 | Reduce 60.98% | 18,337 | $39.36 |
| Q3 2024 | +46,999 | New Buy | 46,999 | $46.98 |
| Q2 2024 | -21,790 | Sold Out | 0 | $0.00 |
| Q1 2024 | +5,741 | Add 35.77% | 21,790 | $68.16 |
| Q4 2023 | +16,049 | New Buy | 16,049 | $62.60 |
| Q3 2023 | -25,562 | Sold Out | 0 | $0.00 |
| Q2 2023 | +25,562 | New Buy | 25,562 | $56.14 |
| Q1 2023 | -24,949 | Sold Out | 0 | $0.00 |
| Q4 2022 | +1,056 | Add 4.42% | 24,949 | $0.04 |
| Q3 2022 | +4,211 | Add 21.40% | 23,893 | $65.33 |
| Q2 2022 | -5,301 | Reduce 21.22% | 19,682 | $60.77 |
| Q1 2022 | -4 | Reduce 0.02% | 24,983 | $62.76 |
| Q4 2021 | +3,701 | Add 17.39% | 24,987 | $75.80 |
| Q3 2021 | +21,286 | New Buy | 21,286 | $111.95 |
| Q1 2021 | -15,841 | Sold Out | 0 | $0.00 |
| Q4 2020 | +8,858 | Add 126.85% | 15,841 | $153.08 |
| Q3 2020 | +1,916 | Add 37.81% | 6,983 | $83.63 |
| Q2 2020 | -6,182 | Reduce 54.96% | 5,067 | $73.42 |
| Q1 2020 | -5,484 | Reduce 32.77% | 11,249 | $42.40 |
| Q4 2019 | +16,733 | New Buy | 16,733 | $60.90 |
| Q2 2018 | -8,608 | Sold Out | 0 | $0.00 |
| Q1 2018 | +8,608 | New Buy | 8,608 | $45.66 |
Paul Tudor Jones's CRISPR Therapeutics Investment FAQs
Paul Tudor Jones first purchased CRISPR Therapeutics AG (CRSP) in Q1 2018, acquiring 8,608 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held CRISPR Therapeutics AG (CRSP) for 25 quarters since Q1 2018.
Paul Tudor Jones's largest addition to CRISPR Therapeutics AG (CRSP) was in Q3 2024, adding 46,999 shares worth $2.21 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 39,468 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $2.07 M.
As of the Q4 2025 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in CRISPR Therapeutics AG (CRSP) was 51,242 shares, as reported at the end of Q1 2025.